BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

ArcherDX picks deal with Invitae over IPO Genetic testing company Invitae (NYSE:NVTA) is acquiring ArcherDX Inc., adding a cancer diagnostics platform to its precision oncology business. ArcherDX’s shareholders will receive $325 million in cash plus...
BioCentury | Apr 19, 2019
Clinical News

Pfizer's 20-valent pneumonia vaccine safe, immunogenic in Phase II

Pfizer said its pneumococcal conjugate vaccine 20vPnC (PF-06482077) was safe and led to "robust" immunogenicity in a Phase II trial to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes contained in the product....
BioCentury | Mar 7, 2018
Distillery Therapeutics


...patients harboring OPA1 mutations. In three neural progenitor cell lines derived from a patient harboring OPA1...
...and survival compared with a tool compound that inhibits apoptosis. In a mouse model of OPA1-mutant...
...include identifying and testing necroptosis inhibitors in tissue samples from patients with OPA1-mutant PD. TARGET/MARKER/PATHWAY: Optic atrophy 1 (OPA1)...
BioCentury | Jun 20, 2016
Company News

Otsuka Pharmaceutical, Acucela deal

Otsuka terminated deals with Acucela to co-develop and co-commercialize Acucela’s emixustat ( ACU-4429 ) and Otsuka’s OPA-6566 . The emixustat deal was signed in 2008 and granted Otsuka co-development rights in North America and exclusive rights in Asia....
BioCentury | Jun 15, 2016
Company News

Acucela slides after Otsuka ends ophthalmic deals

Acucela Inc. (Tokyo:4589) sank Y400 (24%) to Y1,253 on Tuesday after it said Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) terminated co-development deals for Acucela's emixustat (formerly ACU-4429 ) and Otsuka's OPA-6566 . Last month, Acucela said emixustat...
BioCentury | Feb 15, 2016
Company News

Otsuka Pharmaceutical, Medimetriks deal

Otsuka granted Medimetriks exclusive rights to develop and commercialize OPA-15406 in the U.S. The phosphodiesterase-4 (PDE-4) inhibitor has completed a Phase II trial for atopic dermatitis. Otsuka will receive $22 million up front and is...
BioCentury | Dec 7, 2015
Clinical News

Masitinib: Phase III data

Top-line data from a double-blind, international Phase III trial in 135 patients with severe systemic mastocytosis showed that oral masitinib plus concomitant symptomatic treatments met the primary endpoint of a cumulative improvement of >75% from...
BioCentury | Oct 13, 2014
Clinical News

Masican masitinib: Phase III ongoing

An independent DSMB recommended continuation of a double-blind, placebo-controlled, international Phase III trial evaluating 6 mg/kg/day masitinib based on safety and efficacy data. The trial is enrolling about 150 adult mastocytosis patients with severe handicaps/symptoms....
BioCentury | Oct 15, 2012
Clinical News

Prevnar 13: Additional Phase III data

Additional data from 900 healthy adults aged 18-49 in the open-label portion of the Phase III Study 004 trial showed that Prevnar 13 produced immune responses for all 13 serotypes contained in the vaccine that...
BioCentury | Mar 19, 2012
Clinical News

Prevenar 13: Phase III data

Pfizer reported data from an open-label Phase III trial 598 healthy children showing that Prevnar 13 met all study endpoints by demonstrating immunogenicity at 1 month post-vaccination and establishing a safety profile in children aged...
Items per page:
1 - 10 of 17